The EUFOREA pocket guide for chronic rhinosinusitis*

Peter W. Hellings; W. J. Fokkens; R. Orlandi; G. F. Adriaensen; I. Alobid; F. M. Baroody; L. Bjermer; B. A. Senior; A. Cervin; N. A. Cohen; J. Constantinidis; E. De Corso; M. Desrosiers; Z. Diamant; R. G. Douglas; S. Gane; P. Gevaert; J. K. Han; R. J. Harvey; C. Hopkins; R. C. Kern; B. N. Landis; J. T. Lee; S. E. Lee; A. Leunig; V. J. Lund; M. Bernal-Sprekelsen; J. Mullol; C. Philpott; E. Prokopakis; S. Reitsma; D. Ryan; S. Salmi; G. Scadding; R. J. Schlosser; A. Steinsvik; P. V. Tomazic; E. Van Staeyen; T. Van Zele; O. Vanderveken; A. S. Viskens; D. Conti; M. Wagenmann

doi:10.4193/Rhin22.344

The EUFOREA pocket guide for chronic rhinosinusitis*

Peter W. Hellings^*, W. J. Fokkens, R. Orlandi, G. F. Adriaensen, I. Alobid, F. M. Baroody, L. Bjermer, B. A. Senior, A. Cervin, N. A. Cohen, J. Constantinidis, E. De Corso, M. Desrosiers, Z. Diamant, R. G. Douglas, S. Gane, P. Gevaert, J. K. Han, R. J. Harvey, C. HopkinsR. C. Kern, B. N. Landis, J. T. Lee, S. E. Lee, A. Leunig, V. J. Lund, M. Bernal-Sprekelsen, J. Mullol, C. Philpott, E. Prokopakis, S. Reitsma, D. Ryan, S. Salmi, G. Scadding, R. J. Schlosser, A. Steinsvik, P. V. Tomazic, E. Van Staeyen, T. Van Zele, O. Vanderveken, A. S. Viskens, D. Conti, M. Wagenmann

^*Corresponding author for this work

Otolaryngology

Research output: Contribution to journal › Letter › peer-review

46 Scopus citations

Abstract

Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS.

Original language	English (US)
Pages (from-to)	85-89
Number of pages	5
Journal	Rhinology
Volume	61
Issue number	1
DOIs	https://doi.org/10.4193/Rhin22.344
State	Published - 2023

Funding

Funding was provided via an unrestricted grant to EUFOREA by Sanofi Genzyme and Regeneron. Douglas: No conflict of interest to report. S. Gane: lecture fees and/or participation in at expert board meetings of GSK and Sanofi. Trustee for the AbScent and Rhinology and Laryngology Research Fund charities. P. Gevaert: PhG lecture fees and/or participationion at expert board meetings of 3NT, Ablynx, ALK, Argenx, AstraZeneca, Bekaert Textiles, Genentech, GSK, Hall Allergy, Medtronic, Novartis, Regeneron, Roche, Sanofi-Genzyme, Stallergenes-Greer, Teva, and Thermo Fisher. J.K. Han: No conflict of interest to report. R. J Harvey: consultant with Medtronic, Olympus, Novartis and NeilMed pharmaceuticals. He has also been on the speakers’ bureau for Glaxo-Smith-Kline, Meda Pharmaceutical, Seqiris and Astra-Zeneca. Research funding from Neilmed and Glaxo-Smith-Kline. C. Hopkins, R.C. Kern, B.N. Landis: No conflict of interest to report. J. T. Lee: consultant for medtronic, Stryker ent, sanofi, and Aerin medical. S.E. Lee: Clinical trial funding and advisory boards: AstraZeneca, Genentech, Glaxo Smith Kline, Genzyme, Optinose, Sanofi Regeneron. A. Leunig, V. Lund, M. Bernal-Sprekelsen: No conflict of interest to report. J. Mullol: AstraZeneca, Genentech, Inc., GlaxoSmith-Kline, Glenmark, Menarini, Mitsubishi-Tanabe, Merck Sharp & Dohme, Viatris (Mylan-MEDA), Novartis, Proctor & Gamble, W. Fokkens, R. Orlandi, G.F. Adriaensen: No conflict of interest to report. I. Alobid: Consultant for GSK, Novartis, Viatris, Sanofi, Roche, Olympus, and Salvat, F.M. Baroody, L. Bjermer, BA Senior, A. Cervin: No conflict of interest to report. N.A. Cohen: Has received research Funding from NIH-Veterans Affairs Administration; is Founding Partner of 4 Sinuses LLC. Is on the Scientific Advisory Board for Oyster Point Pharmaceuticals, Sanofi/Regeneron and GSK. Is a consultant for AstraZeneca and Bayer Health. Has a Patent: Therapy and Diagnostics for Respiratory Infection PCT/ US2013/023185, WO2013112865 A1. Has a licensing agreement: GeneOne Life Sciences. J. Constantinidis: Has received fees for lectures and participation on expert board meetings from GSK. E. De Corso: Lecture fees and/or participations at expert board meetings of Sanofi, GSK, Novartis, Astrazeneca. M. Desrosiers: has received clinical trial funding from AstraZeneca, GSK, Probio-nase Therapies and Sanofi, has participated in advisory boards for Regeneron Pharmaceuticals, Inc., Sanofi, and holds equity in Probionase Therapies. Z. Diamant: In the past 3 years: acted as consultant for Antabio and QPS-NL and received speaker fees or served on advisory boards for: ALK, Boehringer Ingel-heim, GlaxoSmithKline and Sanofi-Genzyme-Regeneron. R.G.

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.4193/Rhin22.344

Cite this

Hellings, P. W., Fokkens, W. J., Orlandi, R., Adriaensen, G. F., Alobid, I., Baroody, F. M., Bjermer, L., Senior, B. A., Cervin, A., Cohen, N. A., Constantinidis, J., De Corso, E., Desrosiers, M., Diamant, Z., Douglas, R. G., Gane, S., Gevaert, P., Han, J. K., Harvey, R. J., ... Wagenmann, M. (2023). The EUFOREA pocket guide for chronic rhinosinusitis*. Rhinology, 61(1), 85-89. https://doi.org/10.4193/Rhin22.344

@article{941de8c887be4cf38beb57a6a05ff5a7,

title = "The EUFOREA pocket guide for chronic rhinosinusitis*",

abstract = "Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS.",

author = "Hellings, {Peter W.} and Fokkens, {W. J.} and R. Orlandi and Adriaensen, {G. F.} and I. Alobid and Baroody, {F. M.} and L. Bjermer and Senior, {B. A.} and A. Cervin and Cohen, {N. A.} and J. Constantinidis and {De Corso}, E. and M. Desrosiers and Z. Diamant and Douglas, {R. G.} and S. Gane and P. Gevaert and Han, {J. K.} and Harvey, {R. J.} and C. Hopkins and Kern, {R. C.} and Landis, {B. N.} and Lee, {J. T.} and Lee, {S. E.} and A. Leunig and Lund, {V. J.} and M. Bernal-Sprekelsen and J. Mullol and C. Philpott and E. Prokopakis and S. Reitsma and D. Ryan and S. Salmi and G. Scadding and Schlosser, {R. J.} and A. Steinsvik and Tomazic, {P. V.} and {Van Staeyen}, E. and {Van Zele}, T. and O. Vanderveken and Viskens, {A. S.} and D. Conti and M. Wagenmann",

note = "Funding Information: Funding was provided via an unrestricted grant to EUFOREA by Sanofi Genzyme and Regeneron. Funding Information: Douglas: No conflict of interest to report. S. Gane: lecture fees and/or participation in at expert board meetings of GSK and Sanofi. Trustee for the AbScent and Rhinology and Laryngology Research Fund charities. P. Gevaert: PhG lecture fees and/or participationion at expert board meetings of 3NT, Ablynx, ALK, Argenx, AstraZeneca, Bekaert Textiles, Genentech, GSK, Hall Allergy, Medtronic, Novartis, Regeneron, Roche, Sanofi-Genzyme, Stallergenes-Greer, Teva, and Thermo Fisher. J.K. Han: No conflict of interest to report. R. J Harvey: consultant with Medtronic, Olympus, Novartis and NeilMed pharmaceuticals. He has also been on the speakers{\textquoteright} bureau for Glaxo-Smith-Kline, Meda Pharmaceutical, Seqiris and Astra-Zeneca. Research funding from Neilmed and Glaxo-Smith-Kline. C. Hopkins, R.C. Kern, B.N. Landis: No conflict of interest to report. J. T. Lee: consultant for medtronic, Stryker ent, sanofi, and Aerin medical. S.E. Lee: Clinical trial funding and advisory boards: AstraZeneca, Genentech, Glaxo Smith Kline, Genzyme, Optinose, Sanofi Regeneron. A. Leunig, V. Lund, M. Bernal-Sprekelsen: No conflict of interest to report. J. Mullol: AstraZeneca, Genentech, Inc., GlaxoSmith-Kline, Glenmark, Menarini, Mitsubishi-Tanabe, Merck Sharp & Dohme, Viatris (Mylan-MEDA), Novartis, Proctor & Gamble, Funding Information: W. Fokkens, R. Orlandi, G.F. Adriaensen: No conflict of interest to report. I. Alobid: Consultant for GSK, Novartis, Viatris, Sanofi, Roche, Olympus, and Salvat, F.M. Baroody, L. Bjermer, BA Senior, A. Cervin: No conflict of interest to report. N.A. Cohen: Has received research Funding from NIH-Veterans Affairs Administration; is Founding Partner of 4 Sinuses LLC. Is on the Scientific Advisory Board for Oyster Point Pharmaceuticals, Sanofi/Regeneron and GSK. Is a consultant for AstraZeneca and Bayer Health. Has a Patent: Therapy and Diagnostics for Respiratory Infection PCT/ US2013/023185, WO2013112865 A1. Has a licensing agreement: GeneOne Life Sciences. J. Constantinidis: Has received fees for lectures and participation on expert board meetings from GSK. E. De Corso: Lecture fees and/or participations at expert board meetings of Sanofi, GSK, Novartis, Astrazeneca. M. Desrosiers: has received clinical trial funding from AstraZeneca, GSK, Probio-nase Therapies and Sanofi, has participated in advisory boards for Regeneron Pharmaceuticals, Inc., Sanofi, and holds equity in Probionase Therapies. Z. Diamant: In the past 3 years: acted as consultant for Antabio and QPS-NL and received speaker fees or served on advisory boards for: ALK, Boehringer Ingel-heim, GlaxoSmithKline and Sanofi-Genzyme-Regeneron. R.G.",

year = "2023",

doi = "10.4193/Rhin22.344",

language = "English (US)",

volume = "61",

pages = "85--89",

journal = "Rhinology",

issn = "0300-0729",

publisher = "University Hospital Utrecht",

number = "1",

}

Hellings, PW, Fokkens, WJ, Orlandi, R, Adriaensen, GF, Alobid, I, Baroody, FM, Bjermer, L, Senior, BA, Cervin, A, Cohen, NA, Constantinidis, J, De Corso, E, Desrosiers, M, Diamant, Z, Douglas, RG, Gane, S, Gevaert, P, Han, JK, Harvey, RJ, Hopkins, C, Kern, RC, Landis, BN, Lee, JT, Lee, SE, Leunig, A, Lund, VJ, Bernal-Sprekelsen, M, Mullol, J, Philpott, C, Prokopakis, E, Reitsma, S, Ryan, D, Salmi, S, Scadding, G, Schlosser, RJ, Steinsvik, A, Tomazic, PV, Van Staeyen, E, Van Zele, T, Vanderveken, O, Viskens, AS, Conti, D & Wagenmann, M 2023, 'The EUFOREA pocket guide for chronic rhinosinusitis*', Rhinology, vol. 61, no. 1, pp. 85-89. https://doi.org/10.4193/Rhin22.344

TY - JOUR

T1 - The EUFOREA pocket guide for chronic rhinosinusitis*

AU - Hellings, Peter W.

AU - Fokkens, W. J.

AU - Orlandi, R.

AU - Adriaensen, G. F.

AU - Alobid, I.

AU - Baroody, F. M.

AU - Bjermer, L.

AU - Senior, B. A.

AU - Cervin, A.

AU - Cohen, N. A.

AU - Constantinidis, J.

AU - De Corso, E.

AU - Desrosiers, M.

AU - Diamant, Z.

AU - Douglas, R. G.

AU - Gane, S.

AU - Gevaert, P.

AU - Han, J. K.

AU - Harvey, R. J.

AU - Hopkins, C.

AU - Kern, R. C.

AU - Landis, B. N.

AU - Lee, J. T.

AU - Lee, S. E.

AU - Leunig, A.

AU - Lund, V. J.

AU - Bernal-Sprekelsen, M.

AU - Mullol, J.

AU - Philpott, C.

AU - Prokopakis, E.

AU - Reitsma, S.

AU - Ryan, D.

AU - Salmi, S.

AU - Scadding, G.

AU - Schlosser, R. J.

AU - Steinsvik, A.

AU - Tomazic, P. V.

AU - Van Staeyen, E.

AU - Van Zele, T.

AU - Vanderveken, O.

AU - Viskens, A. S.

AU - Conti, D.

AU - Wagenmann, M.

N1 - Funding Information: Funding was provided via an unrestricted grant to EUFOREA by Sanofi Genzyme and Regeneron. Funding Information: Douglas: No conflict of interest to report. S. Gane: lecture fees and/or participation in at expert board meetings of GSK and Sanofi. Trustee for the AbScent and Rhinology and Laryngology Research Fund charities. P. Gevaert: PhG lecture fees and/or participationion at expert board meetings of 3NT, Ablynx, ALK, Argenx, AstraZeneca, Bekaert Textiles, Genentech, GSK, Hall Allergy, Medtronic, Novartis, Regeneron, Roche, Sanofi-Genzyme, Stallergenes-Greer, Teva, and Thermo Fisher. J.K. Han: No conflict of interest to report. R. J Harvey: consultant with Medtronic, Olympus, Novartis and NeilMed pharmaceuticals. He has also been on the speakers’ bureau for Glaxo-Smith-Kline, Meda Pharmaceutical, Seqiris and Astra-Zeneca. Research funding from Neilmed and Glaxo-Smith-Kline. C. Hopkins, R.C. Kern, B.N. Landis: No conflict of interest to report. J. T. Lee: consultant for medtronic, Stryker ent, sanofi, and Aerin medical. S.E. Lee: Clinical trial funding and advisory boards: AstraZeneca, Genentech, Glaxo Smith Kline, Genzyme, Optinose, Sanofi Regeneron. A. Leunig, V. Lund, M. Bernal-Sprekelsen: No conflict of interest to report. J. Mullol: AstraZeneca, Genentech, Inc., GlaxoSmith-Kline, Glenmark, Menarini, Mitsubishi-Tanabe, Merck Sharp & Dohme, Viatris (Mylan-MEDA), Novartis, Proctor & Gamble, Funding Information: W. Fokkens, R. Orlandi, G.F. Adriaensen: No conflict of interest to report. I. Alobid: Consultant for GSK, Novartis, Viatris, Sanofi, Roche, Olympus, and Salvat, F.M. Baroody, L. Bjermer, BA Senior, A. Cervin: No conflict of interest to report. N.A. Cohen: Has received research Funding from NIH-Veterans Affairs Administration; is Founding Partner of 4 Sinuses LLC. Is on the Scientific Advisory Board for Oyster Point Pharmaceuticals, Sanofi/Regeneron and GSK. Is a consultant for AstraZeneca and Bayer Health. Has a Patent: Therapy and Diagnostics for Respiratory Infection PCT/ US2013/023185, WO2013112865 A1. Has a licensing agreement: GeneOne Life Sciences. J. Constantinidis: Has received fees for lectures and participation on expert board meetings from GSK. E. De Corso: Lecture fees and/or participations at expert board meetings of Sanofi, GSK, Novartis, Astrazeneca. M. Desrosiers: has received clinical trial funding from AstraZeneca, GSK, Probio-nase Therapies and Sanofi, has participated in advisory boards for Regeneron Pharmaceuticals, Inc., Sanofi, and holds equity in Probionase Therapies. Z. Diamant: In the past 3 years: acted as consultant for Antabio and QPS-NL and received speaker fees or served on advisory boards for: ALK, Boehringer Ingel-heim, GlaxoSmithKline and Sanofi-Genzyme-Regeneron. R.G.

PY - 2023

Y1 - 2023

N2 - Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS.

AB - Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS.

UR - http://www.scopus.com/inward/record.url?scp=85147143801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85147143801&partnerID=8YFLogxK

U2 - 10.4193/Rhin22.344

DO - 10.4193/Rhin22.344

M3 - Letter

C2 - 36507741

AN - SCOPUS:85147143801

SN - 0300-0729

VL - 61

SP - 85

EP - 89

JO - Rhinology

JF - Rhinology

IS - 1

ER -

The EUFOREA pocket guide for chronic rhinosinusitis*

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this